CapWealth Advisors LLC Has $10.52 Million Position in Stryker Co. (NYSE:SYK)

CapWealth Advisors LLC decreased its position in shares of Stryker Co. (NYSE:SYK) by 2.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 29,226 shares of the medical technology company’s stock after selling 641 shares during the period. CapWealth Advisors LLC’s holdings in Stryker were worth $10,523,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in SYK. BXM Wealth LLC acquired a new position in shares of Stryker during the 4th quarter worth $467,000. PUREfi Wealth LLC bought a new position in Stryker in the fourth quarter valued at about $7,846,000. V Square Quantitative Management LLC raised its stake in Stryker by 7.5% during the fourth quarter. V Square Quantitative Management LLC now owns 5,799 shares of the medical technology company’s stock worth $2,088,000 after acquiring an additional 403 shares in the last quarter. Figure 8 Investment Strategies LLC acquired a new stake in shares of Stryker in the 4th quarter valued at approximately $1,710,000. Finally, Catalyst Financial Partners LLC grew its holdings in shares of Stryker by 5.6% during the 4th quarter. Catalyst Financial Partners LLC now owns 1,450 shares of the medical technology company’s stock valued at $522,000 after purchasing an additional 77 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on SYK shares. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, January 30th. Morgan Stanley upgraded Stryker from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Barclays boosted their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Citigroup raised their price objective on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a report on Wednesday, December 11th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $420.68.

Stryker Trading Down 0.9 %

NYSE:SYK opened at $385.05 on Friday. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The firm’s 50 day moving average is $377.31 and its 200 day moving average is $366.30. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The stock has a market capitalization of $146.79 billion, a PE ratio of 49.62, a price-to-earnings-growth ratio of 2.98 and a beta of 0.96.

Stryker (NYSE:SYK) last issued its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the firm earned $3.46 earnings per share. Sell-side analysts expect that Stryker Co. will post 13.49 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 5.90% of the stock is owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.